NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Higroton
|
Hydro-Long
|
Hygroton
|
Igroton
|
Isoren
|
Natriuran
|
Oradil
|
Phthalamodine
|
Phthalamudine
|
Renon
|
Saluretin
|
Tenoretic
|
Thalitone
|
Zambesil
|
|
|
Synonyms
|
2-Chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-benzenesulfonamide
|
3-Hydroxy-3-[4-chloro-3-sulfamylphenyl]phthalimidine
|
Chlorthalidone
|
Hygroton
|
Igroton
|
Phthalamudine
|
Zambesil
|
NSC 69200
|
Chlorothalidone
|
Chlorphthalidolone
|
Chlorphthalidone
|
Chlortalidone
|
Chlorthalidon
|
Clodronic Acid
|
Chlorthalidone
|
2-Chloro-5-(1-hydroxy-3-oxoisoindolin-1-yl)benzenesulfonamide
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
8.579576
|
H Acceptors
|
4
|
H Donor
|
3
|
LogD (pH = 5.5)
|
1.6031008
|
LogD (pH = 7.4)
|
1.5784703
|
Log P
|
1.6034211
|
Molar Refractivity
|
81.3005 cm3
|
Polarizability
|
31.75829 Å3
|
Polar Surface Area
|
109.49 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
1.27
|
LOG S
|
-3.81
|
Solubility (Water)
|
5.28e-02 g/l
|
DETAILS
DETAILS
DrugBank
TRC
DrugBank -
DB00310
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem] |
Indication |
For management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. |
Pharmacology |
Chlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema. |
Toxicity |
Symptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Liver |
Absorption |
Absorbed relatively rapidly after oral administration. |
Half Life |
40 hours |
Protein Binding |
High (75% [58% to albumin]) |
Elimination |
The major portion of the drug is excreted unchanged by the kidneys. |
External Links |
|
|
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Beisenherz, et al.: Arch. Int. Pharmacodyn. Ther., 161, 76 (1966)
- • Zsoter, et al.: J. Pharmacol. Exp. Ther., 180, 723 (1966)
- • Singer, J.M., et al.: Anal. Profiles Drug Subs., 14, 1 (1966)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent